PPARG and urinary bladder cancer: Thiazolidinediones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists and improve insulin sensitivity [11] although the circulation of some of them has been suspended in Europe due to concerns about cardiovascular safety [12] and increases in bladder cancer incidence [13].